Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.40 |
| ▸ | PDE2A | O00408 | 2/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 4/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | THPO | P40225 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | APEX1 | P27695 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22344636 | 1.00 | KDM4E (0.40) | KDM4ELMNAHIF1APDE2AADRA2A | |
| SCHEMBL15441184 | 0.89 | KDM4E (0.45) | KDM4ELMNAHIF1APDE2AADRA2A | |
| SCHEMBL15441219 | 0.89 | KDM4E (0.45) | KDM4ELMNAHIF1APDE2AADRA2A | |
| SCHEMBL531415 | 0.89 | KDM4E (0.45) | KDM4ELMNAHIF1APDE2AADRA2A | |
| SCHEMBL15828511 | 0.89 | KDM4E (0.45) | KDM4ELMNAHIF1APDE2AADRA2A | |
| SCHEMBL15440915 | 0.89 | KDM4E (0.45) | KDM4ELMNAHIF1APDE2AADRA2A | |
| SCHEMBL3952470 | 0.89 | KDM4E (0.45) | KDM4ELMNAHIF1APDE2AADRA2A | |
| SCHEMBL15934390 | 0.83 | KDM4E (0.50) | KDM4ELMNAHIF1AADRA2AADRA2C | |
| SCHEMBL15927674 | 0.83 | KDM4E (0.40) | KDM4ELMNAHIF1APDE2AADRA2A | |
| SCHEMBL15448858 | 0.83 | KDM4E (0.40) | KDM4ELMNAHIF1APDE2AADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3402777-B1 | OXAZOLIDINONES AS TARO INHIBITORS | MERCK SHARP & DOHME (US) | 2023-12-13 | — | — | EP | disclosed |
| US-11738010-B2 | Oxazolidinones as TarO inhibitors | MERCK SHARP & DOHME CORP. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20210346364-A1 | OXAZOLIDINONES AS TARO INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-11-11 | — | — | US | disclosed |
| US-11141410-B2 | Oxazolidinones as taro inhibitors | MERCK SHARP & DOHME CORP (US) | 2021-10-12 | — | — | US | disclosed |
| US-20200261436-A1 | OXAZOLIDINONES AS TARO INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210346364-A1 | OXAZOLIDINONES AS TARO INHIBITORS | OXA1L, DDO, ALPI | KDM4E 3157/4885LMNA 3204/4885HIF1A 4620/4885 |
| US-20200261436-A1 | OXAZOLIDINONES AS TARO INHIBITORS | OXA1L, DDO, ALPI | KDM4E 3157/4885LMNA 3204/4885HIF1A 4620/4885 |
| US-11141410-B2 | Oxazolidinones as taro inhibitors | OXA1L, DDO, ALPI | KDM4E 3157/4885LMNA 3204/4885HIF1A 4620/4885 |
| US-11738010-B2 | Oxazolidinones as TarO inhibitors | OXA1L, DDO, ALPI | KDM4E 3157/4885LMNA 3204/4885HIF1A 4620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.